Company news

Disc Medicine, Inc. news in 2023

Disc Medicine, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

December 19, 2023

Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting

December 10, 2023

Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting

December 10, 2023

Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin

November 13, 2023

Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update

November 8, 2023

Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates

November 1, 2023

Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce

October 22, 2023

Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers

October 2, 2023

Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera

September 19, 2023

Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update

August 10, 2023

Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)

July 26, 2023

Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 21, 2023

Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

June 12, 2023

Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

June 8, 2023

Disc Medicine to Participate in the Jefferies Healthcare Conference

May 30, 2023

Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update

May 14, 2023

Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

May 10, 2023

Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference

April 20, 2023

Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)

April 12, 2023

Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update

March 30, 2023

Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)

March 20, 2023

Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

February 15, 2023

Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs

February 13, 2023

Disc Medicine to Participate in SVB Securities Global Biopharma Conference

February 7, 2023

Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis

January 19, 2023

Decks in 2023